|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| ==Background==
| | #REDIRECT[[Eosinophilic granulomatosis with polyangiitis]] |
| *Eosinophilic granulomatosis with polyangiitis (EGPA)
| |
| *Chronic sinusitis, asthma, and peripheral eosinophilia
| |
| *Vasculitis of small and medium sized vessels
| |
| *Lung and skin are most commonly involved
| |
| | |
| ==Clinical Features==
| |
| Classically develops in three sequential phases:
| |
| #Prodrome
| |
| #*Atopic diseases, allergic rhinitis, and asthma
| |
| #Eosinophilic phase
| |
| #*Multiorgan involvement, particularly lung and GI tract
| |
| #*Caused by eosinophilic infiltration into these organs
| |
| #Vasculitic phase
| |
| #*Life threatening vasculitis associated with vascular and extravascular granulomatosis
| |
| #*May present with nonspecific signs such as fever, weight loss, malaise
| |
| | |
| ==Differential Diagnosis==
| |
| *Aspirin-exacerbated respiratory disease
| |
| *Chronic eosinophilic pneumonia
| |
| *Allergic bronchopulmonary aspergillosis
| |
| *Hypereosinophilic syndrome
| |
| *Other vasculitides
| |
| | |
| ==Evaluation==
| |
| *Typically a clinical diagnosis
| |
| *Labs with elevated eosinophils, ESR, CRP, ANCA
| |
| *[[CXR]] with transient, patchy opacities
| |
| | |
| ==Management==
| |
| ===Initiation Therapy===
| |
| *[[Prednisone]] 0.5-1.5mg/kg/day
| |
| *Cyclophosphamide
| |
| | |
| ===Maintenance Therapy===
| |
| *Azathioprine
| |
| *Methotrexate
| |
| *Leflunomide
| |
| *Inhaled glucocorticoids
| |
| | |
| ==Disposition==
| |
| *Refer to rheumatology
| |
| | |
| ==See Also==
| |
| | |
| ==External Links==
| |
| | |
| ==References==
| |
| | |
| [[Category:Rheumatology]]
| |
